Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Researchers from Nagoya University detail findings in cancer gene therapy
September 2nd, 2008
A new study, 'Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy,' is now available. According to a study from Nagoya, Japan, "Oncolytic HSV-1 has been developed as a novel anticancer agent. According to the properties and functions of HSV-1 encoded proteins, several genes have been targeted for engineering of oncolytic HSV-1." "As a result, a variety of strategies have been applied to the engineering of oncolytic HSV-1. Success in cancer therapy for solid tumors requires a maximal oncolytic effect; however, recombinant HSV-1 that has been adapted to meet neurotoxicity requirements for the treatment of brain tumors...
Source: Cancer Weekly (2008-09-02)
|
